PURPOSE: To determine if common polymorphisms in the endotoxin recognition complex influence the acute phase response as determined by the development of the systemic inflammatory response syndrome (SIRS) and platelet count on admission. METHODS: This was a prospective observational cohort study. Paediatric intensive care patients (n = 913) were genotyped for common functional polymorphisms in the endotoxin recognition complex, including Toll-like receptor 4 (TLR4). We also selected potentially confounding polymorphisms in other genes of the innate immune system. SIRS was defined by age-specific consensus criteria. Platelet counts were recorded on admission. RESULTS: The development of SIRS was primarily determined by the nature of the insult, but carriers of TLR4 variant alleles had lower platelet counts than children with wild-type genotype [mean +/- standard error of the mean (SEM) 143 +/- 7 vs. 175 +/- 4; p = 0.0001)--independent of other innate immune system polymorphisms. These findings were validated using a patient cohort of 1,170 adults with coronary artery disease. Carriers of TLR4 polymorphisms with a history of myocardial infarction (n = 573) had lower platelet counts than those with the wild-type genotype (217 +/- 7 vs. 237 +/- 2.8; p = 0.021). CONCLUSIONS: Our results show that TLR4 variant alleles are associated with lower platelet counts across a range of ages and precipitating insults but that they do not influence the incidence of SIRS. This result may reflect redundancy and 'robustness' in the pathways leading to SIRS or the lack of specificity of this endpoint. Platelet count may vary with TLR4 genotype because it may be sufficiently sensitive and more linearly related to inflammation than other markers or, alternatively, there may be a direct TLR4-mediated platelet effect.
PURPOSE: To determine if common polymorphisms in the endotoxin recognition complex influence the acute phase response as determined by the development of the systemic inflammatory response syndrome (SIRS) and platelet count on admission. METHODS: This was a prospective observational cohort study. Paediatric intensive care patients (n = 913) were genotyped for common functional polymorphisms in the endotoxin recognition complex, including Toll-like receptor 4 (TLR4). We also selected potentially confounding polymorphisms in other genes of the innate immune system. SIRS was defined by age-specific consensus criteria. Platelet counts were recorded on admission. RESULTS: The development of SIRS was primarily determined by the nature of the insult, but carriers of TLR4 variant alleles had lower platelet counts than children with wild-type genotype [mean +/- standard error of the mean (SEM) 143 +/- 7 vs. 175 +/- 4; p = 0.0001)--independent of other innate immune system polymorphisms. These findings were validated using a patient cohort of 1,170 adults with coronary artery disease. Carriers of TLR4 polymorphisms with a history of myocardial infarction (n = 573) had lower platelet counts than those with the wild-type genotype (217 +/- 7 vs. 237 +/- 2.8; p = 0.021). CONCLUSIONS: Our results show that TLR4 variant alleles are associated with lower platelet counts across a range of ages and precipitating insults but that they do not influence the incidence of SIRS. This result may reflect redundancy and 'robustness' in the pathways leading to SIRS or the lack of specificity of this endpoint. Platelet count may vary with TLR4 genotype because it may be sufficiently sensitive and more linearly related to inflammation than other markers or, alternatively, there may be a direct TLR4-mediated platelet effect.
Authors: Graciela Andonegui; Steven M Kerfoot; Kelly McNagny; Kirsten V J Ebbert; Kamala D Patel; Paul Kubes Journal: Blood Date: 2005-06-16 Impact factor: 22.113
Authors: Serdar Akca; Philip Haji-Michael; Arnaldo de Mendonça; Peter Suter; Marcel Levi; Jean Louis Vincent Journal: Crit Care Med Date: 2002-04 Impact factor: 7.598
Authors: Stefan Kiechl; Eva Lorenz; Markus Reindl; Christian J Wiedermann; Friedrich Oberhollenzer; Enzo Bonora; Johann Willeit; David A Schwartz Journal: N Engl J Med Date: 2002-07-18 Impact factor: 91.245
Authors: Bart Ferwerda; Matthew Bb McCall; Karlijn Verheijen; Bart-Jan Kullberg; André Jam van der Ven; Jos Wm Van der Meer; Mihai G Netea Journal: Mol Med Date: 2008 May-Jun Impact factor: 6.354
Authors: Pierre-Yves Bochud; Jason W Chien; Kieren A Marr; Wendy M Leisenring; Arlo Upton; Marta Janer; Stephanie D Rodrigues; Sarah Li; John A Hansen; Lue Ping Zhao; Alan Aderem; Michael Boeckh Journal: N Engl J Med Date: 2008-10-23 Impact factor: 91.245
Authors: Cheng-Lung Ku; Horst von Bernuth; Capucine Picard; Shen-Ying Zhang; Huey-Hsuan Chang; Kun Yang; Maya Chrabieh; Andrew C Issekutz; Coleen K Cunningham; John Gallin; Steven M Holland; Chaim Roifman; Stephan Ehl; Joanne Smart; Mimi Tang; Franck J Barrat; Ofer Levy; Douglas McDonald; Noorbibi K Day-Good; Richard Miller; Hidetoshi Takada; Toshiro Hara; Sami Al-Hajjar; Abdulaziz Al-Ghonaium; David Speert; Damien Sanlaville; Xiaoxia Li; Frédéric Geissmann; Eric Vivier; László Maródi; Ben-Zion Garty; Helen Chapel; Carlos Rodriguez-Gallego; Xavier Bossuyt; Laurent Abel; Anne Puel; Jean-Laurent Casanova Journal: J Exp Med Date: 2007-09-24 Impact factor: 14.307
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2011-02-03 Impact factor: 17.440